CYSTOID MACULAR EDEMA SECONDARY TO RETINITIS PIGMENTOSA

Dr. Ganga Mahesh kadiyala

Abstract


AIM AND OBJECTIVE:
Ÿ To assess the efficacy of oral acetazolamide in
management of CME secondary to retinitis pigmentosa.
Ÿ To evaluate anatomical and visual outcome following
treatment
Ÿ To determine the duration of treatment


Full Text:

PDF

References


Abigail T Fahim, Stephen P Daiger, Richard G Weleber. Retinitis Pigmentosa Overview. Gene Reviews. March 21, 2013.

Garg S. Retinitis pigmentosa: treatment. UpToDate. May 12 2015.

Zarbin M. Cell-Based Therapy for Degenerative Retinal Disease. Trends in Molecular Medicine. February 2016; 22(2):115-34.

Roska B, Busskamp V, Sahel JA, Picaud S. [Retinitis pigmentosa: eye sight restoration by optogenetic therapy]. Biol Aujourdhui. 2013;207(2).

He Y, Zhang Y, Liu X, Ghazaryan E, Li Y, Xie J, Su G. Recent advances of stem cell therapy for retinitis pigmentosa. Int J Mol Sci. 2014 Aug 20;15(8):14456-74.

Pach J, Gekeler F. [Therapeutic approaches for retinitis pigmentosa]. KlinMonbl Augenheilkd. 2013 May;230(5):512-8.

Fishman GA, Fishman M, Maggiano J: Macular lesions associated with retinitis pigmentosa. Arch Ophthalmol 1977;95:798-803.

Heckenlively JR: RP cone-rod degeneration. Trans Am Ophthalmol Soc 1987;85:438-470.

Pruett RC: Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc 1983;81:693-735.

Adackapara CA, Sunness JS, Dibernardo CW, et al: Prevalence of cystoid macular edema and stability in oct retinal thickness in eyes with retinitis pigmentosa during a 48-week lutein trial. Retina 2008;28:103-110.


Refbacks

  • There are currently no refbacks.